Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Application symbols : Alny save search
Alnylam Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Published: 2023-10-09 (Crawled : 14:30) - biospace.com/
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: 0.19%
H: 0.0%
C: 0.0%
ALNY | $147.775 -0.49% -0.49% 490K
|
Health Technology
|
| O: -4.06%
H: 2.17%
C: -0.83%
fda drug treatment application response
Alnylam Stock Trading Halted Today; FDA Advisory Committee to Review Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Published: 2023-09-13 (Crawled : 12:00) - biospace.com/
SNYNF | $92.9 -2.18% 880
|
Health Technology
|
| O: -1.8%
H: 0.0%
C: 0.0%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: -0.99%
H: 0.0%
C: 0.0%
fda drug review treatment application
Alnylam Announces U.S. Food and Drug Administration (FDA) Acceptance of Supplemental New Drug Application for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Published: 2023-02-21 (Crawled : 14:00) - biospace.com/
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: 0.79%
H: 0.0%
C: 0.0%
ALNY | $147.775 -0.49% -0.49% 490K
|
Health Technology
|
| O: -2.68%
H: 0.6%
C: -7.83%
onpattro treatment drug application food
Alnylam Submits CTA Application for ALN-KHK, an Investigational RNAi Therapeutic for the Treatment of Type 2 Diabetes
Published: 2022-12-21 (Crawled : 13:20) - biospace.com/
SNYNF | $92.9 -2.18% 880
|
Health Technology
|
| O: 6.05%
H: 2.65%
C: 0.66%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: 2.63%
H: 0.0%
C: 0.0%
ALNY | $147.775 -0.49% -0.49% 490K
|
Health Technology
|
| O: -0.05%
H: 2.34%
C: 1.64%
treatment application diabetes
Alnylam Submits Supplemental New Drug Application (sNDA) to U.S. Food and Drug Administration (FDA) for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Published: 2022-12-08 (Crawled : 22:00) - biospace.com/
SNYNF | $92.9 -2.18% 880
|
Health Technology
|
| O: 0.5%
H: 0.16%
C: 0.16%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: -1.32%
H: 0.0%
C: 0.0%
ALNY | $147.775 -0.49% -0.49% 490K
|
Health Technology
|
| O: 0.43%
H: 3.16%
C: 2.44%
onpattro treatment drug application food
Alnylam Announces 3-Month Extension of Review Period for New Drug Application for Vutrisiran
Published: 2022-04-04 (Crawled : 12:00) - biospace.com/
ALNY | $147.775 -0.49% -0.49% 490K
|
Health Technology
|
| O: -1.2%
H: 0.26%
C: -3.28%
drug application review
Alnylam Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for OXLUMO® for the Treatment of Advanced Primary Hyperoxaluria Type 1
Published: 2022-03-01 (Crawled : 16:00) - biospace.com/
SNYNF | $92.9 -2.18% 880
|
Health Technology
|
| O: -3.33%
H: 0.0%
C: 0.0%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: -1.3%
H: 0.0%
C: 0.0%
ALNY | $147.775 -0.49% -0.49% 490K
|
Health Technology
|
| O: 0.65%
H: 3.47%
C: 2.28%
oxlumo new drug treatment application drug food
Alnylam Submits CTA Application for ALN-APP, an Investigational RNAi Therapeutic for the Treatment of Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Published: 2021-12-22 (Crawled : 13:00) - biospace.com/
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: -0.59%
H: 1.12%
C: 0.93%
ALNY | $147.775 -0.49% -0.49% 490K
|
Health Technology
|
| O: -5.24%
H: 2.44%
C: -0.93%
alzheimer treatment application disease alzheimer’s alzheimer's disease alzheimer's
Alnylam Submits CTA Application for ALN-XDH, an Investigational RNAi Therapeutic for the Treatment of Gout
Published: 2021-12-20 (Crawled : 12:30) - biospace.com/
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: -0.59%
H: 0.18%
C: -0.2%
ALNY | $147.775 -0.49% -0.49% 490K
|
Health Technology
|
| O: 6.14%
H: 2.21%
C: 1.59%
treatment application
Alnylam Submits Regulatory Applications to the U.S. Food and Drug Administration and European Medicines Agency to Support Label Expansion for OXLUMO® for the Treatment of Advanced Primary Hyperoxaluria Type 1
Published: 2021-12-14 (Crawled : 12:30) - biospace.com/
SNYNF | $92.9 -2.18% 880
|
Health Technology
|
| O: -3.62%
H: 0.0%
C: -0.56%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: -0.51%
H: 0.0%
C: 0.0%
ALNY | $147.775 -0.49% -0.49% 490K
|
Health Technology
|
| O: 6.02%
H: 2.03%
C: -0.29%
oxlumo treatment europe application expansion drug food
Dicerna Announces FDA Clearance of Investigational New Drug (IND) Application for DCR-AUD for the Treatment of Alcohol Use Disorder
Published: 2021-07-29 (Crawled : 21:00) - biospace.com/
NVO | $123.9 -0.49% 0.23% 2.9M
|
Health Technology
|
| O: 0.49%
H: 0.26%
C: -0.62%
LLY | $750.77 -0.12% 0.0% 2.3M
|
Health Technology
|
| O: 0.4%
H: 0.3%
C: -0.88%
ALNY | $147.775 -0.49% -0.49% 490K
|
Health Technology
|
| O: -0.01%
H: 1.3%
C: -0.14%
new drug alcohol use disorder fda clearance treatment fda drug application clearance
Dicerna Announces FDA Acceptance of Lilly’s Investigational New Drug (IND) Application for LY3819469
Published: 2021-05-27 (Crawled : 13:00) - biospace.com/
NVO | $123.9 -0.49% 0.23% 2.9M
|
Health Technology
|
| O: -1.58%
H: 0.7%
C: -0.32%
LLY | $750.77 -0.12% 0.0% 2.3M
|
Health Technology
|
| O: -0.17%
H: 0.36%
C: -0.72%
ALNY | $147.775 -0.49% -0.49% 490K
|
Health Technology
|
| O: 0.57%
H: 1.91%
C: 0.46%
new drug fda fda acceptance drug application
Gainers vs Losers
| 49% | 51% |
Top 10 Gainers
KAVL | $6.275 135.02% 57.45% 44M
|
Wholesale Trade
PXMD | $0.7375 79.09% 44.16% 4.5M
|
Health Technology
DYNT | $0.371 -5.12% 43.09% 3.3M
|
Health Technology
LGVN P 3 d | $2.94 73.96% 42.52% 57M
|
HUBC | $1.94 49.23% 32.99% 73M
|
n/a
SPCB | $0.4044 46.52% 31.75% 130M
|
Electronic Technology
ONVO | $1.34 32.66% 24.62% 54M
|
Health Technology
OMQS | $0.6869 32.1% 24.3% 3.6M
|
Professional, Scientific, and T...
SNPO | $10.555 29.67% 22.88% 4M
|
AMBI | $3.72 -26.77% 21.77% 9.8K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.